This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Kalyn, R. Search for Related Content PubMed PubMed Citation Articles by Kalyn, R. Pubmed/NCBI databases Medline Plus Health Information Cancer Cancer Chemotherapy Social Bookmarking                         What's this?

Overview of targeted therapies in Oncology

Pharmacy Communities Oncology Network Educator, BC Cancer Agency - Centre for the Southern Interior, 399 Royal Ave, Kelowna, BC, Canada V1Y 5L3, rkalyn{at}bccancer.bc.ca

Background: Recent scientific advances have provided a map of the human genome along with a better understanding of the processes that transform healthy cells into diseased cells. This has led to the emergence of a new class of drugs called targeted therapies.

Objective: To describe the classifications and basic pharmacology of targeted therapies.

Methods: A literature search was performed for peer reviewed journal articles using Medline (1996—2007), Embase (1996—2007) and Google. The search was performed using keywords such as angiogenesis inhibitors, cancer vaccines, gene therapy, monoclonal antibodies, small molecules, proteasome inhibitors, targeted therapy and tyrosine kinase inhibitors.

Conclusions: A review of the basic pharmacology is described in this article, including the following major categories of targeted therapies: • Small molecule drugs • Monoclonal antibodies • Apoptosis-inducing drugs • Angiogenesis Inhibitors • Cancer vaccines • Gene therapy J Oncol Pharm Practice (2007) 13: 199—205.

Key Words: angiogenesis inhibitors antineoplastic agents • antisense oligonucleotides • cancer vaccines • drug therapy • epidermal growth factor inhibitors • gene theropy monoclonal antibodies • oncogenes • pharmacology • protease inhibitors • small molecules • suicide genes • targeted therapy • tumor suppressor genes • tyrokinase inhibitors • vascular endothelial growth factor inhibitors

References

• Viele CS Keys to unlock cancer: targeted therapy. Oncol Nurs Forum 2005; 32: 935—40.[CrossRef][Medline] [Order article via Infotrieve]
• Capriotti T. New oncology strategy: molecular targeting of cancer cells. Medsurg Nurs 2004; 13: 191—5.[Medline] [Order article via Infotrieve]
• Summerhayes M. What targeted therapy for cancer is and how it is achieved: a review. The Pharmaceutical Journal 2006; 277: 518—25.
• PDQ® Cancer Information Summary. National Cancer Institute; Bethesda MD. Targeted Cancer Therapies: Questions and Answers [Online]. 2004 [cited 2006 Sep 03; Available from: http://www.nci.nih.gov/cancertopics/factsheet/Therapy/targeted
• Spencer J. Targeted drugs for cancer treatment. Pharmacy Practice 2006; 22: 1—7.
• Nelson M. Concepts in targeted cancer therapy. US Pharmacist 2005; 30: 18—23.
• Segota E., Bukowski RM The promise of targeted therapy: cancer drugs become more specific. Cleve Clin J Med 2004; 71: 551—60.[Abstract/Free Full Text]
• Ross JS, Schenkein DP, Pietrusko R., Rolfe M., Linette GP, Stec J. et al. Targeted therapies for cancer 2004. Am J Clin Pathol 2004; 122: 598—609.[CrossRef][Medline] [Order article via Infotrieve]
• Uro Today. Wyeth Submits NDA and MAA for Torisel for the Treatment of Advanced Renal Cell Carcinoma. 2006 October 09 [cited 2006 December 8; Available from: http://www.urotoday.com/38/browse_categories/renal_cancer/wyeth_submits_nda_and_maa_for_torisel_for_the_treatment_of_advanced_renal_cell_carcinoma.html
• Mauro MJ Defining and managing imatinib resistance. Hematology Am Soc Hematol Educ Program Book 2006 — The American Society of Hematology 2006; 219—25.
• Hayes D. Chemotherapy for metastatic breast cancer. In: UpToDate Rose B, ed. Waltham, MA 2007.
• Kuo CJ Overview of angiogenesis inhibitors. In: UpToDate Rose B, ed. Waltham, MA 2007.
• Summerhayes M. Challenges in tumour targeting. The Pharmaceutical Journal 2006; 277: 550—2.
• PDQ® Cancer Information Summary. National Cancer Institute. NCI Drug Dictionary. [cited 2006 December 14; Available from: http://www.cancer.gov/drugdictionary/
• B.C. Cancer Agency. Focus on Infusion Reactions from Monoclonal Antibodies. Systemic Therapy Update [serial online] 2004 May [cited 2006 Oct 12; 7: 4—5:[Available from: http://www.bccancer.bc.ca/HPI/systemictherapyarchive.htm
• U.S. Food and Drug Administration. FDA Approves New Combination Therapy for Lung Cancer. 2006 [cited 2006 Nov 9; Available from: http://www.fda.gov/bbs/topics/NEWS/2006/NEW01488.HTML
• UpToDate. Panitumumab: Drug information. In: UpToDate Rose B, ed. Waltham, MA 2007.
• PDQ® Cancer Information Summary. National Cancer Institute. Understanding Cancer Series: Angiogenesis. 2005 [cited 2007 Mar 19; Available from: http://www.cancer.gov/cancertopics/understandingcancer/angiogenesis
• PDQ® Cancer Information Summary. National Cancer Institute; Bethesda MD. Angiogenesis Inhibitors in Clinical Trials [Online]. 1999 [cited 2006 Sep 03; Available from: http://www.cancer.gov/clinicaltrials/developments/anti-angio-table/print?page=&keyword
• PDQ® Cancer Information Summary. National Cancer Institute; Bethesda MD. Cancer Vaccine Fact Sheet [Online]. 2003 [cited 2006 Sep 3; Available from: http://www.nci.nih.gov/cancertopics/factsheet/cancervaccine
• Waknine Y. International Approvals: Singulair and Gardasil/Silgard. Medscape Medical News 2006 October 2 [cited 2006 December 13; Available from: http://www.medscape.com/viewarticle/545374
• Cross D., Burmester JK Gene therapy for cancer treatment: past, present and future. Clin Med Res 2006; 4: 218—27.[Abstract/Free Full Text]
• Zlokovic BV, Apuzzo ML Cellular and molecular neurosurgery: pathways from concept to reality—part I: target disorders and concept approaches to gene therapy of the central nervous system. Neurosurgery 1997; 40: 789—803; discussion-4.[CrossRef][Medline] [Order article via Infotrieve]
• Su ZZ, Madireddi MT, Lin JJ, Young CS, Kitada S., Reed JC et al. The cancer growth suppressor gene mda-7 selectively induces apoptosis in human breast cancer cells and inhibits tumor growth in nude mice. Proc Natl Acad Sci USA 1998; 95: 14400—5.[Abstract/Free Full Text]
• Zhao L., Samuels T., Winckler S., Korgaonkar C., Tompkins V., Horne MC et al. Cyclin G1 has growth inhibitory activity linked to the ARF-Mdm2-p53 and pRb tumor suppressor pathways. Mol Cancer Res 2003; 1: 195—206.
• Morse M. Technology evaluation: Rexin-G, Epeius Biotechnologies. Curr Opin Mol Ther 2005; 7: 164—9.

Journal of Oncology Pharmacy Practice, Vol. 13, No. 4, 199-205 (2007)
DOI: 10.1177/1078155207080804


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Kalyn, R. Search for Related Content PubMed PubMed Citation Articles by Kalyn, R. Pubmed/NCBI databases Medline Plus Health Information Cancer Cancer Chemotherapy Social Bookmarking                         What's this?